{"DataElement":{"publicId":"4379853","version":"1","preferredName":"Patient Negative Pregnancy Test  Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator for eligibility relating to a negative pregnancy test for a patient.","longName":"PT_NG_PRGTST_COD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2201733","version":"1","preferredName":"Patient Negative Pregnancy Test","preferredDefinition":"information relating to a negative pregnancy test for a patient.","longName":"PT_NEGATIVE_PREGTEST","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177068","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"Patient","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AB6-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207514","version":"1","preferredName":"Negative Pregnancy test","preferredDefinition":"Negative; involving disadvantage or harm.:Tests to determine whether or not an individual is pregnant.","longName":"C25247:C0032976","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negative","conceptCode":"C25247","definition":"Involving disadvantage or harm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pregnancy test","conceptCode":"C0032976","definition":"Tests to determine whether or not an individual is pregnant.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-2697-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2C45BCA-71CD-7026-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-03-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876423","version":"1","longName":"Consents & Contraceptive Guidelines","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"PT_NG_PRGTST_COD_IND","type":"USED_BY","context":"Theradex"},{"name":"PBTC","type":"USED_BY","context":"PBTC"}],"ReferenceDocuments":[{"name":"If patient is woman of childb","type":"Preferred Question Text","description":"If patient is woman of childbearing potential, is serum or urine pregnancy test done within 72 hours before the start of investigational product, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"If patient is female of childbearing potential is serum pregnancy test done less than or equal to 7 days prior to registration, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is urine pregnancy test done within 7 days of initiation of treatment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum pregnancy test done within 14 days prior to registration, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is pregnancy test done at screening, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG), negative within 24 hours prior to the start of Nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is pregnancy test (serum or urine), negative?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 7 days and within 24 hours prior to the first dose of GDC-0449 (serum or urine), negative?  A positive urine test must be confirmed by serum pregnancy test.","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"If female of childbearing potential, is pregnancy test at screening negative?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient is female of childbearing potential is serum pregnancy test done less than or equal to 7 days prior to start of therapy, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum pregnancy test done within 14 days prior to start of protocol treatment, negative?","url":null,"context":"Theradex"},{"name":"Theradex -11","type":"Alternate Question Text","description":"Is serum pregnancy test negative?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum or urine pregnancy test done within 7 days of registration, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is pregnancy test done within 72 hours or enrollment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is urine pregnancy test done within 7 days prior to initiation of treatment negative?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum or urine pregnancy test done within 72 hours before the start of study medication, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum or urine pregnancy test done within 24 hours before the start of investigational product, negative?","url":null,"context":"Theradex"},{"name":"PBTC_Text2","type":"Alternate Question Text","description":"Female patient of childbearing potential will have two pregnancy tests: once within 10-14 days prior to starting pomalidomide (can include the enrollment test) AND again within 24 hours prior to initiation of pomalidomide, and patient will only proceed with enrollment if both pregnancy tests are negative?","url":null,"context":"PBTC"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Female patients of childbearing potential have a negative serum or urine pregnancy test at the time of enrollment?","url":null,"context":"PBTC"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum or urine pregnancy test (with a sensitivity of at least 25 mIU/mL) within 10 - 14 days and within 24 hours of starting lenalidomide, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum pregnancy test negative?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Is serum pregnancy test done within 7 days prior to treatment initiation, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"If patient is woman of child bearing potential, is pregnancy test done prior to study entry, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG), negative within 24 hours prior to the start ofÂ treatment on the study?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum pregnancy test done within 72 hours of enrollment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum or urine pregnancy test done within 72 hours before the start of first cycle of therapy, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum pregnancy test done within 14 days prior to enrollment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum pregnancy test done within 14 days prior to randomization, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Is female patient post-menopausal, has evidence of non-childbearing status as defined in the protocol or if of childbearing potential is urine or serum pregnancy test done within 7 days prior to treatment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum pregnancy test done less than or equal to 28 days prior first dose of study treatment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Is female patient post-menopausal or has evidence of non-childbearing status as defined in the protocol, or if of childbearing potential is urine or serum pregnancy test done within 28 days of study treatment and confirmed by serum pregnancy test within 7 days prior to treatment on day 1, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"If female of childbearing potential, is serum pregnancy test at screening negative?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum or urine pregnancy test done within 72 hours prior to receiving first dose of study medication, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"If female, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin [B-hCG]) at the Screening Visit and the Baseline Visit done within 72 hours of the first dose of study drug, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"If patient is female of child-bearing or non-child bearing potential, is serum or urine pregnancy test done within 3 days prior to start of study treatment negative?\r\n","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum or urine pregnancy test done at screening, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Is patient post-menopausal or if of child-bearing potential is urine or serum pregnancy test done within 28 days of study treatment and confirmed prior to treatment on day 1, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum pregnancy test done within 72 hours prior to enrollment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG), negative within 24 hours prior to the start of Nivolumab with or without ipilimumab?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG), negative within 24 hours prior to the start of nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"If patient is female of childbearing potential is pregnancy test done less than or equal to 7 days prior to registration, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Is female patient post-menopausal or has evidence of non-childbearing status as defined in the protocol, or if of childbearing potential is urine or serum pregnancy test done within 28 days of study treatment and confirmed by serum pregnancy test prior to treatment on day 1, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"If patient is of childbearing potential, is pregnancy test negative?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"If patient is female, is there evidence of post-menopausal status or if pre-menopausal is urine or serum pregnancy test, no more than 7 days before study entry, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Does female patient of childbearing potential have a negative pregnancy test or has evidence of non-childbearing potential at screening as noted in protocol and is not breastfeeding?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is urine or serum pregnancy test done within 7 days prior to registration negative and serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG), negative within 24 hours prior to the start of nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is urine or serum pregnancy test done within 72 hours before receiving the first dose of study agent(s), negative?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"If patient is female of childbearing potential is urine or serum pregnancy test done within 7 days prior to registration negative and serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG), negative within 24 hours prior to the start of nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum pregnancy test done within 72 hours prior to the first dose of study drug, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG), negative?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG), negative within 24 hours prior to the start of nivolumab and patient is not breastfeeding?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"If patient is a woman of childbearing potential, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin [B-HCG]) during the screening period, negative OR female patient under the age of 55 have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL to be considered postmenopausal?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of study enrollment or randomization, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"If patient is female, is there evidence of post-menopausal status or if pre-menopausal is urine or serum pregnancy test, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"Is patient postmenopausal, or there is evidence of non-childbearing status or if of child bearing potential, is serum or urine pregnancy test done within 28 days of study treatment and confirmed prior to treatment on day 1, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum pregnancy test done within 7 days prior to registration, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Is patient postmenopausal, or there is evidence of non-childbearing status or if patient is of child bearing potential, was a serum or urine pregnancy test done within 28 days of study treatment and confirmed negative prior to treatment on day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"Is female patient post-menopausal or has evidence of non-childbearing status as defined in the protocol, or if of childbearing potential was a negative urine or serum pregnancy test done within 28 days of study treatment and confirmed prior to treatment on day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"If patient is female of childbearing potential, has negative urine or serum pregnancy test been performed within 28 days of study treatment and confirmed prior to day 1 of treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"If patient is of woman of childbearing potential, is serum or urine pregnancy test done within 72 hours prior to receiving first dose of study medication, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"If patient is female of childbearing potential, has a negative serum or urine human chorionic gonadotropin (HCG) pregnancy test been performed, unless patient has had a prior tubal ligation(greater than or equal to 1 year before screening, total hysterectomy or menopause (defined  as 12 consecutive months of amenorrhea)?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is pregnancy test done within 7 days of starting treatment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum or urine pregnancy test done within 72 hours prior to receiving the first dose of 7+3 treatment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 64","type":"Alternate Question Text","description":"Does female have negative serum or urine pregnancy test within 14 days prior to study entry and again within 24-hours prior to day 1 of lenalidomide?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is urine pregnancy test done within 8 days prior to both enrollment and start of protocol therapy, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 65","type":"Alternate Question Text","description":"If patient is women of childbearing potential, is serum or urine pregnancy test conducted within 72 hours prior to DS-8201a administration at baseline, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) done within 1 week of registration, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is pregnancy test done prior to beginning study treatment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"If patient is a woman of childbearing potential, has a negative serum or urine pregnancy test been performed within 72 hours prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 70","type":"Alternate Question Text","description":"If patient is female of childbearing potential, does patient have a negative urine or serum pregnancy test within 30 days before randomization and within 72 hours before the first administration of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 69","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum or urine pregnancy test done within 72 hours prior to the start of receiving the first dose of the study medication, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 71","type":"Alternate Question Text","description":"Does patient, women of childbearing potential, have a negative urine or serum pregnancy test at screening?","url":null,"context":"Theradex"},{"name":"Theradex - 72","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is urine or serum pregnancy test done within 28 days of initial dose of rogaratinib (BAY 1163877) and again within 7 days prior to treatment on day 1, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 76","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, does patient have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to the start of nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 74","type":"Alternate Question Text","description":"Is patient postmenopausal or there is evidence of non-childbearing status OR a negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 77","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is urine or serum pregnancy test done within 10-14 days prior to and within 24 hours of starting pomalidomide, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 78","type":"Alternate Question Text","description":"If patient is female of childbearing potential (FCBP), is pregnancy test 72 hours prior to the start of study therapy negative?","url":null,"context":"Theradex"},{"name":"Theradex - 73","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, does patient have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 7 days of the first dose of abemaciclib?","url":null,"context":"Theradex"},{"name":"Theradex - 79","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is urine or serum pregnancy test done within 72 hours before receiving the first dose of the study agent, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 75","type":"Alternate Question Text","description":"Does female patient have a negative pregnancy test?","url":null,"context":"Theradex"},{"name":"Theradex - 81","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) at the time of enrollment and within 8 days prior to each cycle, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum pregnancy test done within 14 days prior to start of protocol treatment and confirmed prior to treatment on day 1, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 80","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is urine or serum pregnancy test done within 30 days before enrollment and within 72 hours before receiving the first dose of study treatment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 82","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum or urine pregnancy test negative?","url":null,"context":"Theradex"},{"name":"Theradex - 84","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is urine or serum pregnancy test done within 8 days prior to beginning treatment and again on cycle 1 day 1 of treatment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 85","type":"Alternate Question Text","description":"If patient is female of childbearing potential, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG), negative within 24 hours prior to the start of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 86","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is pregnancy test done prior to study entry, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 83","type":"Alternate Question Text","description":"If patient is female, is there evidence of post-menopausal status or negative urinary or serum pregnancy test if patient is pre-menopausal?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum pregnancy test done within 8 days prior to start of protocol treatment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 87","type":"Alternate Question Text","description":"If patient is a woman of child-bearing potential, is serum or urine HCG test negative unless prior tubal ligation (greater than or equal to 1 year before screening), total hysterectomy, or menopause (defined as 12 consecutive months of amenorrhea)?","url":null,"context":"Theradex"},{"name":"Theradex - 88","type":"Alternate Question Text","description":"If patient is female, is there evidence of post-menopausal status (as defined in protocol) or negative screening urinary or serum pregnancy test for female pre-menopausal patients?","url":null,"context":"Theradex"},{"name":"Theradex - 89","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum or urine pregnancy test done within 14 days prior to registration, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 90","type":"Alternate Question Text","description":"Is patient post-menopausal or if of childbearing potential is   urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on Day 1, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 91","type":"Alternate Question Text","description":"If patient is a woman of childbearing potential, is pregnancy test prior to receiving sunitinib malate negative?","url":null,"context":"Theradex"},{"name":"Theradex - 92","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin [B-HCG]) negative, during the screening period?","url":null,"context":"Theradex"},{"name":"Theradex - 93","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, does patient have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to the start of nivolumab and duvelisib?","url":null,"context":"Theradex"},{"name":"Theradex - 94","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, is pregnancy test done prior to study entry and within 7 days of starting treatment, negative?","url":null,"context":"Theradex"},{"name":"Theradex - 95","type":"Alternate Question Text","description":"Is there evidence of post-menopausal status or if patient is pre-menopausal is urine or serum pregnancy test negative?","url":null,"context":"Theradex"},{"name":"Theradex - 96","type":"Alternate Question Text","description":"If patient female of childbearing potential (FCBP) are two pregnancy tests performed within 10-14 days and within 24 hours prior to prescribing lenalidomide negative?","url":null,"context":"Theradex"},{"name":"Theradex - 98","type":"Alternate Question Text","description":"If patient is woman of childbearing potential, does patient have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of investigational product?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6CCF-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeDescription":"2020-7-27 AQT added for Theradex protocol 10389. AK Theradex_ghd_07-02-14","administrativeNotes":"2023.8.8 AQT added per ticket request CADSR0002710. ak 2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"}}